# US 2017/0319648 A1 · High activity tumour inhibitor and preparation method and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0319648 A1
- Document ID: US20170319648A1
- Status: Published application
- Kind: A1
- Application number: 15/519,753
- Filed: 2015-10-15
- Published: 2017-11-09
- Earliest claimed: 2014-10-17
- Assignees: Bao Kang Biomedical Healthcare Inc
- Applicants: Bao Kang Biomedical Healthcare Inc
- Inventors: Kangshan LI
- Web page: https://patentgrep.com/patent/US20170319648A1

## CPC

- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 35/00: Antineoplastic agents
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided in the present invention are a YAP protein inhibiting polypeptide and application thereof. In particular, the present invention obtains a key binding site of YAP protein and TEAD, screens a polypeptide with best YAP inhibitory activity and modifies the polypeptide, such as adding a disulfide linkage, replacing an amino acid, removing and/or adding (for example, adding a cell-penetrating element), and finally screens and verifies the obtaining of a series of polypeptides with YAP protein activity inhibiting effect and good stability. Experiments show that the polypeptide of the present invention can effectively inhibit the binding activity between YAP protein and TEAD, thus providing good therapeutic effect on digestive tract tumors (especially liver cancer).

## Claims

### Claim 1

An isolated polypeptide, wherein the polypeptide has a structure as shown in formula A:
X0-Y1-Y2-Y3-Y4-Y5-Y6-Y7-XA-XE-XF (A)
wherein,
X0 or XA is not present, or is 1, 2, 3, or 4 amino acid residues;
Y1 is AP, VP, or not present;
Y2 is X1-X2-X2a, wherein X1 is selected from M, F, C or Hcy; X2 is an arbitrary amino acid residue (preferably X2 is C, Hcy, L, M, or F); and X2a is L, Nle, C, Hcy, K or R;
Y3 is X3a-X3-X4, wherein X3a is alkaline amino acid R or K; X3 is an arbitrary amino acid (preferably X3 is K, R, Hcy, C, Orn or Dab); and X4 is an arbitrary amino acid (preferably X4 is L, Nle, Hcy, or C), and at least one amino acid of Y3 is Hcy or C;
Y4 is P;
Y5 is X5, and X5 is an arbitrary amino acid (preferably X5 is A, D, or E);
Y6 is S-X6a-X6, wherein X6a is F, C, or Hcy; and X6 is an arbitrary amino acid residue (preferably X6 is C, Hcy, F, K or R);
Y7 is X7-P-X7a, wherein X7 is an arbitrary amino acid residue (preferably X7 is C, Hcy, K, R or P); and X7a is C, Hcy or P;
XE is not present or is a cell-penetrating element;
XF is not present or K;
and the polypeptide exhibits an inhibitory activity on Yes-associated protein (YAP).

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein at least one amino acid of Y2 and/or Y3 is Hcy or C; and at least one amino acid of Y6 or Y7 is Hcy or C.

### Claim 3 (depends on 1)

The polypeptide of claim 1, wherein at least one pair of disulfide linkage is formed, optionally between residues of X1, X2, X2a, X3, X3a, X5, X6, X6a, X7 and X7a.

### Claim 4 (depends on 1)

The polypeptide of claim 1 which has a structure as shown in formula V:
X0-Z-XA-XE-XF (V)
wherein,
X0 or XA is not present, or is 1, 2, 3, or 4 amino acid residues;
XE is not present or is a cell-penetrating element;
XF is not present or K;
Z is a YAP inhibiting polypeptide having an introduced intra-chain disulfide linkage,
and Z has a basic sequence as shown in formula Va after the corresponding amino acids for forming intra-chain disulfide linkages are removed:
Z1-Z2-Z3-Z4- Z5-Z6-Z7-Z8-Z9-Z10-Z11-Z12-Z13-Z14-Z15-Z16 Formula Va
wherein,
Z1 is V, A, or not present;
Z2 is P, A, or not present;
Z3 is M, F, L, or chlorophenylalanine ((Cl)F);
Z4 is R, K, A, or not present;
Z5 is L, Nle, A, or not present;
Z6 is R, or K;
Z7 is K, R, Orn, Dab, or A;
Z8 is L, or Nle;
Z9 is P;
Z10 is any natural or unnatural amino acid, and preferably D, A, V, L, I or E;
Z11 is S, or T;
Z12 is F, L, or chlorophenylalanine;
Z13 is F, L, chlorophenylalanine or not present;
Z14 is K, R, A, or not present;
Z15 is P, A, or not present;
Z16 is P, A, or not present;
wherein, the first amino acid B1 of disulfide linkage is located between any two amino acids in a first segment formed by Z1 to Z8 in the basic sequence or is located before the first amino acid of the first segment, and the second amino acid B2 of disulfide linkage is located between any two amino acids in a second segment formed by Z9 to Z16 in the basic sequence or is located after the last amino acid of the second segment.

### Claim 5 (depends on 4)

The polypeptide of claim 4, wherein the first amino acid B1 is located between Z2 and Z3, between Z3 and Z4, between Z3 and Z5 (when Z4 is not present), between Z4 and Z5, or between Z7 and Z8, and/or
the second amino acid B2 is located between Z11 and Z12, between Z12 and Z13, between Z13 and Z14, after Z14 (when Z15 and Z16 is not present), after Z15 (when Z16 is not present), or after Z16.

### Claim 6 (depends on 4)

The polypeptide of claim 4, wherein a distance between the disulfide linkage is 4, 5, 6, 7, 8, 9, or 10 amino acids, wherein the amino acids forming the disulfide linkage are excluded; and
preferably, the distance is 5, 6, 7, 8, or 9 amino acids.

### Claim 7 (depends on 4)

The polypeptide of claim 4, wherein the polypeptide has a structure as shown in formula I:
X0-VP-X1-X2-LRX3-X4-P-X5-SF-X6-X7-PP-XA-XE-XF (I)
wherein the polypeptide has the following characteristics:
(a) X0 or XA is not present, or is 1, 2, 3, or 4 amino acid residues;
(b) X1 is selected from M or F;
(c) each of X2, X5, X6 or X7 independently is an arbitrary amino acid residue, and there is at least one pair of disulfide linkage which is formed optionally among X2, X5, X6 and X7;
(d) X3 or X4 is an arbitrary amino acid; and
(e) XE is not present or a cell-penetrating element;
(f) XF is not present or K;
and the polypeptide exhibits an inhibitory activity on Yes-associated protein (YAP).

### Claim 8 (depends on 4)

The polypeptide of claim 4, wherein the polypeptide has a sequence as shown in any of SEQ ID NOs.: 1-12, and 22-37.

### Claim 9 (depends on 1)

A modified polypeptide which is formed by acylation of a polypeptide of claim 1.

### Claim 10 (depends on 9)

The modified polypeptide of claim 9, which has a structure as shown in formula B:
PO-XG formula B
wherein, XG is a C10-C24 acyl, and P0 is a polypeptide of formula A or V.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising the polypeptide according to claim 1 or an acylated polypeptide thereof or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim at position 12

12-13. (canceled)

### Claim 14 (depends on 1)

A method for treating a tumor, which comprises a step of:
administering a safe and effective amount of a polypeptide of claim 1 to a subject in need.

### Claim 15 (depends on 14)

The method of claim 14, wherein the tumor is a tumor with a YAP overexpression.

### Claim 16 (depends on 14)

The method of claim 14, wherein, the tumor is selected from the group consisting of: liver cancer, gastric cancer, colorectal cancer, gallbladder cancer, and pancreatic cancer.
